Latvia - latvisk - Zāļu valsts aģentūra

stallergenes, france - alergēnu ekstrakts - aerosols lietošanai zem mēles, šķīdums - 0,1-1-10-100 vai 300 ri/ml vai 0,1-1-10 vai 100 ki/ml

Latvia - latvisk - Zāļu valsts aģentūra

stallergenes, france - alergēnu ekstrakts - suspensija injekcijām

Latvia - latvisk - Zāļu valsts aģentūra

stallergenes, france - alergēnu ekstrakts - Šķīdums ādas dūriena testam - 100 ri/ml;100 ki/ml vai 1000 ki/ml

Latvia - latvisk - Zāļu valsts aģentūra

stallergenes, france - ziedputekšņi alergēnu produktiem - tablete lietošanai zem mēles - 300 ir

Latvia - latvisk - Zāļu valsts aģentūra

stallergenes, france - ziedputekšņi alergēnu produktiem - tablete lietošanai zem mēles - 100 ir & 300 ir

Latvia - latvisk - Zāļu valsts aģentūra

alk-abello a/s, denmark - pļcavas timotiņa ziedputekšņu ekstrakts - liofilizāts lietošanai zem mēles - 75000 sq-t

Den europeiske union - latvisk - EMA (European Medicines Agency)

amryt pharmaceuticals dac - dry extract from birch bark (der 5-10 : 1), extraction solvent n-heptane 95% (w/w) - epidermolysis bullosa dystrophica; epidermolysis bullosa, junctional - preparāti brūču un čūlas ārstēšanai - treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (eb) in patients 6 months and older.

Den europeiske union - latvisk - EMA (European Medicines Agency)

amryt ag - betulae cortex - wounds and injuries; wound healing - preparāti brūču un čūlas ārstēšanai - daļiņu biezuma brūču ārstēšana pieaugušajiem. skatīt nodaļas 4. 4 un 5. 1 informācija par produktu attiecībā uz pētīto brūču veidu.

Den europeiske union - latvisk - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - zāles obstruktīvu elpceļu slimību, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Den europeiske union - latvisk - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - zāles obstruktīvu elpceļu slimību, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).